As a start-up biotech, AnaptysBio Inc. (NASDAQ: ANAB)didn't feel it necessary to conduct an earnings call after reporting first-quarter results after the bell on Tuesday. The company didn't record any revenue during the first three months of the year, but it did shore up the case for its lead assets.
AnaptysBio Sets the Stage for an Eventful Year
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться